Table 4.
Post-Transplantation Treatment Regimens
| Treatment Regimen | Post-Transplantation Diagnosis |
|||||||
|---|---|---|---|---|---|---|---|---|
| CLL (n = 40) |
RT (n = 32) |
|||||||
| Given First |
Given |
Given First |
Given |
|||||
| No. | % | No. | % | No. | % | No. | % | |
| Rituximab* | 13 | 33 | 17 | 43 | 5 | 20 | 8 | 25 |
| Thalidomide or lenalidomide with or without rituximab | 3 | 8 | 10 | 25 | 3 | 9 | 8 | 25 |
| Alemtuzumab with or without rituximab | 5 | 13 | 10 | 28 | 1 | 3 | 3 | 9 |
| Ofatumumab | 3 | 8 | 11 | 28 | 2 | 6 | 6 | 19 |
| Purine analog-based regimen† | 3 | 8 | 8 | 20 | 0 | 3 | 9 | |
| BR/FBR | 1 | 3 | 6 | 15 | 0 | 2 | 6 | |
| R-hyperCVAD/OFAR | 2 | 5 | 11 | 28 | 9 | 28 | 30 | 94 |
| R-ICE/R-EPOCH/R-DHAP/R-ESHAP | 0 | 0 | 4 | 13 | 6 | 19 | ||
| R-CHOP/R-COP | 1 | 3 | 2 | 5 | 1 | 3 | 1 | 3 |
| Ibrutinib | 1 | 3 | 5 | 13 | 0 | 0 | ||
| Radiation | 0 | 3 | 8 | 0 | 6 | 19 | ||
| Donor lymphocyte infusion‡ | NA | 16 | 40 | NA | 17 | 53 | ||
| Second allogeneic SCT | 0 | 2 | 5 | 0 | 2 | 6 | ||
| Other treatment | 2 | 5 | 4 | 10 | 2 | 6 | 14 | 44 |
| No treatment§ | 0 | 4 | 10 | 0 | 1 | 3 | ||
Abbreviations: BR, bendamustine, rituximab; CLL, chronic lymphocytic leukemia; FBR, cyclophosphamide, bendamustine, rituximab; NA, not available; R-hyperCVAD, rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; OFAR, oxaliplatin, fludarabine, cytarabine, rituximab; R-ICE, rituximab, ifosfamide, cisplatin, etoposide; R-EPOCH, rituximab, etoposide, prednisone, vincristine, doxorubicin; R-DHAP, dexamethasone, doxorubicin, cytarabine, cisplatin; R-ESHAP, rituximab, etoposide, methylprednisolone, cytarabine, cisplatin; R-CHOP, rituximab, cyclophosphamide, vincristine, prednisone, doxorubicin; R-COP, rituximab, cyclophosphamide, vincristine, prednisone; RT, Richter's transformation.
Rituximab given as single treatment or in combination with a steroid and/or granulocyte-macrophage colony-stimulating factor.
Purine analog–based regimens included fludarabine, cyclophosphamide, and rituximab (FCR); cyclophosphamide, fludarabine, cytarabine, and rituximab (CFAR); or pentostatin, cyclophosphamide, and rituximab (PCR).
Patients who received only donor lymphocyte infusion are not included.
Other treatments included IPI-145; chimeric antigen receptor T cells; cytarabine with cladribine; flavopiridol; bafetinib; anti-CD23 antibodies; 8-chloroadenosine; 6-mercaptopurine, vincristine, methotrexate, and prednisone (POMP); azacitidine; and clofarabine.